Newsroom

Blog

Genomics in Precision Medicine

We often hear “Don’t take anything personally”. However, that is not the case in terms of precision medicine. In 2015, the U.S. government launched the "Precision Medicine Initiative".

Read More
Written By:
QinqinZha.jpg
Qinqin Zha

Talking Cancer: Conversations with Trailblazers, Advocates, Patients and Medical Ambassadors

As a premier reference lab and global pharma services organization that runs over a million oncology tests annually, NeoGenomics Laboratories, Inc.

Read More
Written By:
MadhuGhosh.jpg
Madhu Ghosh

Trends – Epigenetic Biomarkers

In the oncology biomarker field, there are obvious trends in technology and markers as well as testing strategies.

Read More

Jemperli blog post - please share your thoughts!

We were glad to see FDA’s combined approval for GSK’s Jemperli (dostarlimab) and Ventana’s MMR RxDx for recurrent or advanced endometrial cancer back in April.

Read More
Written By:
scottreid.jpg
Scott Reid

Biomarker Types and CDx Biomarkers

The field of precision medicine is rooted in biomarker guided therapy. These biomarkers come in various forms as well as are categorized depending on use cases.

Read More
Written By:
JamesYen.jpg
James Yen

Liquid Biopsies

Despite the terminology “liquid biopsies” (LBx) becoming common place in diagnostic lexicon, as a routine clinical technology, LBx is still very much in its infancy.

Read More
Written By:
JamesYen.jpg
James Yen

TriCon 2021 Perspective

It was no surprise that Molecular Med Tri-Con 2021 was a virtual event this year.

Read More
Written By:
JamesYen.jpg
James Yen

Why does IHC remain so popular for CDx development?

The topic of IHC came up recently. Specifically, why is it used so frequently for companion diagnostic development.

Read More
Written By:
scottreid.jpg
Scott Reid

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients